For families living with glycogen storage disease type Ia, the alarm clock is a medical device. Every three to four hours — through dinner, through homework, through the middle of the night — someone stirs raw cornstarch into water and drinks it. Miss a dose and blood sugar can crash. That has been the standard of care for decades, and until last week it was the only thing standing between many patients and a seizure.
On Aug. 19, 2026, the U.S. Food and Drug Administration granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr), the first therapy ever cleared to address the underlying genetic cause of GSDIa rather than only manage its symptoms. Made by Ultragenyx Pharmaceutical of Novato, California, and known during development as DTX401, it is a one-time infusion that uses an AAV8 viral vector to carry a working copy of the G6PC gene into liver cells — the gene that makes glucose-6-phosphatase, the enzyme patients are missing. Without it, the liver cannot release stored glucose between meals, and hypoglycemia becomes a constant threat.
What the trial showed
Approval rests on the 48-week Phase 3 GlucoGene study, which enrolled 46 participants aged 8 to 37 and randomly assigned them to a single infusion of the gene therapy or placebo. Daily cornstarch intake fell about 41% in the treated group versus roughly 10% on placebo, from a baseline of about 290 grams a day, while glucose control held. Treated patients also dropped roughly one cornstarch dose per day. Among 15 treated participants with data out to week 96, intake was about 61% below pre-treatment levels. The therapy is approved specifically to reduce daily cornstarch intake alongside continued nutritional management — not to replace it — and patients in the studies stayed under specialist dietary care. The most common safety issue was a temporary rise in liver enzymes, managed with corticosteroids started about two weeks after infusion.
"Until today, the only thing standing between a person living with GSDIa and a life-threatening episode of hypoglycemia was cornstarch taken as a slurry every three to four hours around the clock, day and night," said Emil Kakkis, Ultragenyx's founder and chief executive, in the company's announcement.
Why it matters to a very small community
GSDIa, also called von Gierke disease, is ultra-rare: The Children's Fund for Glycogen Storage Disease Research estimates it affects roughly 600 people in the United States and about 6,000 worldwide, though other tallies run higher. David and Wendy Feldman, co-founders of that fund, said families organize every day around "strict schedules, overnight vigilance" and the fear that one missed dose could turn dangerous.
Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research, called the decision a milestone in using gene therapy to treat the disease and improve quality of life for people who have it. Because the clearance came through the accelerated pathway, based on cornstarch reduction rather than long-term outcomes, Ultragenyx must supply two more years of data from 50 commercially treated patients plus 20 people who cannot receive the therapy because of pre-existing AAV8 antibodies; company officials said they plan to follow patients for a decade. The therapy carries a list price of about $2.7 million and is expected to reach qualified treatment centers within 30 to 60 days.
It is not a cure, and no one is throwing out the cornstarch box yet. But for a community that has waited nearly 30 years for something aimed at the root of the problem, a few uninterrupted hours of sleep is its own kind of medicine.
